[go: up one dir, main page]

WO2008015383A3 - Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer - Google Patents

Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer Download PDF

Info

Publication number
WO2008015383A3
WO2008015383A3 PCT/GB2007/002755 GB2007002755W WO2008015383A3 WO 2008015383 A3 WO2008015383 A3 WO 2008015383A3 GB 2007002755 W GB2007002755 W GB 2007002755W WO 2008015383 A3 WO2008015383 A3 WO 2008015383A3
Authority
WO
WIPO (PCT)
Prior art keywords
bmp
breast
prostate cancer
cancer therapies
therapies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/002755
Other languages
English (en)
Other versions
WO2008015383A2 (fr
WO2008015383A8 (fr
Inventor
Wen Guo Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Publication of WO2008015383A2 publication Critical patent/WO2008015383A2/fr
Publication of WO2008015383A3 publication Critical patent/WO2008015383A3/fr
Anticipated expiration legal-status Critical
Publication of WO2008015383A8 publication Critical patent/WO2008015383A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne le rôle des protéines BMP-9 et/ou BMP-10 dans le traitement du cancer du sein ou de la prostate.
PCT/GB2007/002755 2006-07-29 2007-07-20 Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer Ceased WO2008015383A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0615129.4 2006-07-29
GBGB0615129.4A GB0615129D0 (en) 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies

Publications (3)

Publication Number Publication Date
WO2008015383A2 WO2008015383A2 (fr) 2008-02-07
WO2008015383A3 true WO2008015383A3 (fr) 2008-08-14
WO2008015383A8 WO2008015383A8 (fr) 2009-07-16

Family

ID=37006438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002755 Ceased WO2008015383A2 (fr) 2006-07-29 2007-07-20 Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer

Country Status (2)

Country Link
GB (1) GB0615129D0 (fr)
WO (1) WO2008015383A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314617B1 (fr) 2004-07-23 2015-06-24 Acceleron Pharma Inc. Polypeptides du récepteur ActRII
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA015105B1 (ru) 2005-11-23 2011-06-30 Акселерон Фарма Инк. Антагонисты активина - actriia и их применение для стимулирования роста кости
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN107050424A (zh) 2007-02-01 2017-08-18 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW202104248A (zh) 2007-02-02 2021-02-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2481415B1 (fr) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Compositions comprenant des antagonistes Activin-ActRIIA
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
WO2009084739A1 (fr) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp10
WO2009084738A1 (fr) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp9
TWI748373B (zh) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010083034A1 (fr) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Procédés permettant d'augmenter l'adiponectine
CA2764890A1 (fr) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Procede visant a augmenter le nombre d'adipocytes thermogenes
MX387164B (es) 2009-06-12 2025-03-19 Acceleron Pharma Inc Proteínas de fusión actriib-fc truncadas.
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP3308796B1 (fr) 2012-11-02 2021-07-14 Celgene Corporation Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
WO2017032856A2 (fr) 2015-08-25 2017-03-02 Histide Ag Composés destinés à induire une formation de tissu et utilisations de ces composés
PL3349776T3 (pl) * 2015-09-17 2021-08-02 Histide Ag Związek farmaceutyczny agonisty receptora czynnika wzrostu i inhibitora białka adhezyjnego do przekształcania komórki nowotworowej w komórkę nienowotworową i jego zastosowanie
ES2900480T3 (es) * 2015-09-17 2022-03-17 Histide Ag Asociaciones farmacéuticas de agonistas de receptores de factor de crecimiento e inhibidores de proteínas de adhesión para la conversión de células neoplásicas en células no neoplásicas y usos de las mismas
WO2023069447A1 (fr) * 2021-10-18 2023-04-27 The Uab Research Foundation Bmp9 ou agoniste de celui-ci et ses utilisations en rapport avec la réduction des métastases du cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435243A2 (fr) * 1998-11-13 2004-07-07 Curis, Inc. Procédés servant à soulager les symptomes du cancer
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
WO2006029406A2 (fr) * 2004-09-09 2006-03-16 Stryker Corporation Methodes de traitement de tumeurs osseuses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435243A2 (fr) * 1998-11-13 2004-07-07 Curis, Inc. Procédés servant à soulager les symptomes du cancer
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
WO2006029406A2 (fr) * 2004-09-09 2006-03-16 Stryker Corporation Methodes de traitement de tumeurs osseuses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 11 March 2004 (2004-03-11), ROSEN C.A. ET AL.: "New albumin fusion proteins useful for preparing a composition for treating diabetes mellitus", XP002474103, retrieved from WWW.EBI.AC.UK accession no. ADH22105 *
SONG J.J. ET AL.: "Bone morphogentic protein-9 binds to liver cells and stimulates proliferation.", ENDOCRINOLOGY, vol. 136, no. 10, 1995, pages 4293 - 4297, XP002474102 *
VARADY P. ET AL.: "Morphologic analysis of BMP-9 gene therapy induced osteogenesis.", HUMAN GENE THERAPY, vol. 12, 10 April 2001 (2001-04-10), pages 697 - 710, XP002474101 *

Also Published As

Publication number Publication date
WO2008015383A2 (fr) 2008-02-07
WO2008015383A8 (fr) 2009-07-16
GB0615129D0 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
WO2008015383A8 (fr) Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer
WO2008076278A3 (fr) Procédés de traitements
IL184617A0 (en) Dr5 antibodies and uses thereof
WO2007127010A3 (fr) Composés de diarylthiohydantoïne
EP1893196A4 (fr) Composes diarylhydantoines
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
IL199609A0 (en) Antifolate agent combinations in the treatment of cancer
WO2009013543A3 (fr) Agents de liaisons ciblés dirigés vers kdr, et utilisations de ceux-ci - 035
WO2009053041A3 (fr) Identification de marqueurs associés aux tumeurs à des fins de diagnostic et de thérapie
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2008150530A3 (fr) Molécules de liaison de cripto
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
MX2012001513A (es) Uso de melanocortinas para tratar la dislipidemia.
ZA200709542B (en) Combination therapy in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2009074253A3 (fr) Dérivés de phospholipide de clofarabine
WO2008009895A3 (fr) Matriptase-2
WO2008061048A3 (fr) Procédés et compositions permettant de diagnostiquer et de traiter le cancer de la prostate
WO2009046123A3 (fr) Antagonistes de nlrr-1 et leurs utilisations
AU2005339587A8 (en) Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
ZA200810524B (en) Pyrimidine derivatives useful in the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2